These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 12845629

  • 1. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas.
    Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, de Jong S.
    J Pathol; 2003 Jul; 200(3):327-35. PubMed ID: 12845629
    [Abstract] [Full Text] [Related]

  • 2. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I.
    Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619
    [Abstract] [Full Text] [Related]

  • 3. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S, Koike N, Adachi S.
    J Cancer Res Clin Oncol; 2002 Feb 01; 128(2):73-9. PubMed ID: 11862476
    [Abstract] [Full Text] [Related]

  • 4. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction.
    Koornstra JJ, Jalving M, Rijcken FE, Westra J, Zwart N, Hollema H, de Vries EG, Hofstra RW, Plukker JT, de Jong S, Kleibeuker JH.
    Eur J Cancer; 2005 May 01; 41(8):1195-202. PubMed ID: 15911244
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.
    J Clin Oncol; 2006 Nov 01; 24(31):4998-5004. PubMed ID: 17075118
    [Abstract] [Full Text] [Related]

  • 6. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 7. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S.
    Clin Cancer Res; 2003 Aug 15; 9(9):3397-405. PubMed ID: 12960128
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D, Réveiller M, Florin A, Blanchard C, Ruffion A, Devonec M, Benahmed M, Grataroli R.
    J Cell Physiol; 2006 Mar 15; 206(3):709-17. PubMed ID: 16245307
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
    Kumamoto H, Ooya K.
    J Oral Pathol Med; 2005 May 15; 34(5):287-94. PubMed ID: 15817072
    [Abstract] [Full Text] [Related]

  • 12. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
    Johnsen JI, Pettersen I, Ponthan F, Sveinbjørnsson B, Flaegstad T, Kogner P.
    Int J Oncol; 2004 Dec 15; 25(6):1849-57. PubMed ID: 15547726
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
    van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ.
    Proc Natl Acad Sci U S A; 2006 Jun 06; 103(23):8634-9. PubMed ID: 16731632
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL, Zou WY, Song LH, Wei W.
    Cancer Chemother Pharmacol; 2005 Feb 06; 55(2):189-96. PubMed ID: 15290100
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.